ALK inhibitors do not increase sensitivity to radiation in EML4-ALK non-small cell lung cancer
K Fleschutz, L Walter, R Leistner… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: ALK inhibitors like Crizotinib, Ceritinib and Alectinib are targeted therapies
used in patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell …
used in patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell …
ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non–small cell lung cancer expressing EML4-ALK
Y Sun, KA Nowak, NG Zaorsky, CL Winchester… - Molecular cancer …, 2013 - AACR
Crizotinib (PF02341066) is a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK)
that has been shown to selectively inhibit growth of cancer cells that harbor the EML4-ALK …
that has been shown to selectively inhibit growth of cancer cells that harbor the EML4-ALK …
Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer
Y Dai, Q Wei, C Schwager, M Moustafa, C Zhou… - Radiotherapy and …, 2015 - Elsevier
Background and purpose Non-small cell lung cancer (NSCLC) patients with chromosomal
rearrangements of the anaplastic lymphoma kinase gene (ALK) are sensitive to the tyrosine …
rearrangements of the anaplastic lymphoma kinase gene (ALK) are sensitive to the tyrosine …
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma …
SA Antoniu - Expert Opinion on Therapeutic Targets, 2011 - Taylor & Francis
Introduction: In lung adenocarcinoma, certain mutations such as echinoderm microtubule-
associated protein-like 4-anaplastic lymphoma kinase (ALK) are associated with lower …
associated protein-like 4-anaplastic lymphoma kinase (ALK) are associated with lower …
[HTML][HTML] Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
Y Dai, Q Wei, C Schwager, J Hanne, C Zhou… - Radiation …, 2018 - Springer
Abstract Background Patients with Echinoderm microtubule-associated protein-like 4
(EML4)-anaplastic lymphoma kinase (ALK) positive lung cancer are sensitive to ALK-kinase …
(EML4)-anaplastic lymphoma kinase (ALK) positive lung cancer are sensitive to ALK-kinase …
Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients.
RC Doebele, DL Aisner, AT Le, EM Berge, AB Pilling… - 2012 - ascopubs.org
7504 Background: Patients with anaplastic lymphoma kinase (ALK) gene fusions derive
significant clinical benefit from crizotinib, an ALK inhibitor; moreover, next generation ALK …
significant clinical benefit from crizotinib, an ALK inhibitor; moreover, next generation ALK …
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy
Rearrangements in anaplastic lymphoma kinase (ALK) gene and echinoderm microtubule-
associated protein-like 4 (EML4) gene were first described in a small portion of patients with …
associated protein-like 4 (EML4) gene were first described in a small portion of patients with …
Overcoming resistance by ALK compound mutation (I1171S+ G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
K Takahashi, Y Seto, K Okada, S Uematsu… - Thoracic …, 2020 - Wiley Online Library
Background Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of non‐
small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK …
small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK …
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Purpose: EML4–ALK fusions define a subset of lung cancers that can be effectively treated
with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is …
with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is …
A mouse model for EML4-ALK-positive lung cancer
M Soda, S Takada, K Takeuchi… - Proceedings of the …, 2008 - National Acad Sciences
EML4-ALK is a fusion-type protein tyrosine kinase that is generated in human non-small-cell
lung cancer (NSCLC) as a result of a recurrent chromosome inversion, inv (p21p23) …
lung cancer (NSCLC) as a result of a recurrent chromosome inversion, inv (p21p23) …
Related searches
- eml4 alk lung cancer
- synergistic effects lung cancer
- alk inhibitors sequential treatment
- alk inhibitors overcoming resistance
- alk fusion synergistic effects
- radiation oncology alk eml4
- effect of radiotherapy alk eml4
- carbon ions alk eml4
- alk inhibitors differential resistance
- alk fusion lung cancer
- radiotherapy with photons alk eml4
- oncogene addiction alk eml4